Researchers look back at how doctors treated blood cancer patients
NCT ID NCT07357441
Summary
This study looked back at medical records of 355 myelofibrosis patients in Turkey who were treated with the drug ruxolitinib. Researchers collected information about patient characteristics, treatment approaches, and outcomes between 2015 and 2022. The goal was to understand how this blood cancer was managed in real-world clinical practice after the drug became available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States
Conditions
Explore the condition pages connected to this study.